A Systems Biology Approach to Characterize Biomarkers for Blood Stasis Syndrome of Unstable Angina Patients by Integrating MicroRNA and Messenger RNA Expression Profiling

Jie Wang and Gui Yu

Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Science, Beixiange 5, Xicheng District, Beijing 100053, China

Correspondence should be addressed to Gui Yu; cliffyugui@sina.com

Received 4 February 2013; Revised 22 March 2013; Accepted 29 March 2013

1. Introduction

Unstable angina (UA) constitutes a clinical syndrome subset of the acute coronary syndrome (ACS) and is associated with an increased risk of cardiac death and subsequent myocardial infarction (MI) [1]. UA is diagnosed by electrocardiographic (ECG) ST-segment depression or prominent T-wave inversion and negative biomarkers of necrosis and in an appropriate clinical setting (chest discomfort or angina equivalent). Its pathophysiological origins relate to disruption or erosion of an atherosclerotic plaque and a subsequent cascade of pathological processes that decrease coronary blood flow [2]. UA remains a severe burden on society and family in both industrialized and developing countries. Although anti-ischemic, antiplatelet, and anticoagulant/antithrombotic therapies and early standard coronary revascularization procedures have been used for fighting against UA, there are some drawbacks of current therapeutics, such as aspirin resistance and adverse effects of statin [3, 4]. New thoughts need to be present for developing efficient diagnosis and optimal therapeutics to combat UA.

Traditional Chinese medicine (TCM) is rapidly gaining attention in the world as sources for discovering new cardiovascular drugs [5–9]. However, simply copying TCM therapy to the treatment of UA is not feasible. Some systematic reviews have shown that the benefits of standard TCM therapies given to UA patients are not always obvious [10, 11]. We think that the main problem is that these clinical trials did not consider the further stratification of UA patients based on TCM syndrome differentiation. Since a single disease can have several kinds of syndromes, it should be treated with different therapies instead of one single therapy [12–14]. According to TCM theory, blood stasis (“Xueyu” in Chinese Mandarin) is one of the key pathogenesis of UA. This has been confirmed by a binary logistic regression analysis of a multicenter prospective research on TCM Syndromes in 815
cases of UA [15]. Blood stasis syndrome (BSS) refers to a condition in which any pathological change is characterized by retarded or impeded blood flow. The local manifestations of BSS include mass formation, ecchymosis or petechiae, and stabbing or pricking pain fixed in location and accompanied by tenderness. The general manifestations of BSS include darkish complexion, skin texture becoming thickened, lack of smooth feeling, dark purple tongue with purple spots, and choppy or irregular pulse. Since BSS is one of the most common syndromes in TCM, lots of research has been done about it [16–21]. The grading system in quantifying BSS diagnosis standards has been built by clinical investigation and multifactorial analysis, and regressive analysis as well as differential analysis in China since 1988 [16, 22]. The grading system can be adapted to all kinds of BSS patients, including UA patients.

Among the classic teachings of TCM, it is stated that “when blockage is opened, pain is relieved; when blockage is not opened, pain persists.” If a UA patient has BSS, the treatment should be promoting blood circulation and removing blood stasis (PBCRBS). The concept of PBCRBS is similar to the modern revascularization method, but it is a kind of macroscopic thinking achieved by drugs rather than microscopic mechanism. The benefit of PBCRBS in UA patients with BSS has been demonstrated by increasing clinical evidences in recent years [23, 24]. It again confirms the importance of considering the further stratification of UA based on TCM syndrome differentiation in clinical trials. More importantly, it gives valuable impetus to the hypothesis that BSS of UA in TCM may have its own specific biomarkers. Exploring these biomarkers may facilitate further risk stratification of UA and provide some new therapeutic targets for treating UA.

MicroRNAs (miRNAs) are endogenous, nonprotein-coding, single-stranded, small RNAs that are generally regarded as negative regulators of gene expression by inhibiting translation and/or promoting messenger RNA (mRNA) degradation [25]. In various cardiovascular diseases, gain- and loss-of-function studies using in vitro and in vivo models have revealed pathogenic and protective functions of miRNAs; therefore they emerge as interesting novel candidates for the development of miRNA-based therapeutic strategies in cardiovascular disease [26]. Besides their function, recent studies have been demonstrated that miRNAs can circulate in the blood of cardiovascular-diseased patients in a remarkably stable form [27]. The discovery of circulating miRNAs opens up intriguing possibilities to use the circulating miRNAs’ patterns as biomarker for cardiovascular diseases. Therefore, circulating miRNAs’ patterns are likely to provide supplementary information for investigating biomedical mechanisms of BSS of UA patients and characterizing its biomarkers.

The purpose of this study was to investigate circulating miRNAs’ patterns of BSS of UA patients by a systems biology approach. MiRNA and mRNA expression profiliings of peripheral blood mononuclear cells (PBMCs) of BSS of UA patients were compared to ones of PBMCs of healthy controls to identify the differentially expressed miRNAs and mRNAs by using a gene expression oligonucleotide microarray and a microRNA microarray. Bioinformatics analysis was used to find critically deregulated miRNAs and mRNAs involved in pathogenesis of BSS of UA and potential biomarkers. The expression patterns of miRNA and mRNA biomarkers in BSS of UA patients were independently validated by real-time quantitative polymerase chain reaction (qRT-PCR) in an independent validation cohort including BSS of UA patients, non-BSS of UA patients, and healthy controls.

2. Materials and Methods

2.1. Patients and Controls. Patients with UA undergoing clinically indicated coronary angiography were consecutively recruited into the study in Guang, Anmen Hospital, Beijing, China. The diagnosis of coronary artery disease (CAD) was confirmed in all patients by coronary angiography showing at least one vessel disease (>50% narrowing of luminal diameter). UA patients were eligible to participate if they had met the American College of Cardiology/American Heart Association (ACC/AHA) criteria for UA [1]. All UA patients (n = 65) had experienced ischemic chest pain within the preceding 48 h, including angina pectoris with an accelerating pattern, or prolonged duration (>20 min), or recurrent episodes at rest or within minimal effort, but with no evidence of enzymatic criteria. Transient ST-T segment depression and/or T-wave inversion were present in all cases. In patients undergoing percutaneous coronary intervention, all blood samples were taken before this procedure.

UA patients were diagnosed as BSS or non-BSS according to the grading system in quantifying BSS diagnosis standards. It had 33 items for diagnosis, including symptoms, signs, and laboratory tests (Table I). Each item had an assigned point. If the grade of 33 items of the diagnostic scale of BSS in a patient was more than 19, the patient could be diagnosed as BSS. If the grade of 33 items in a patient was less than 19, the patient could be diagnosed as non-BSS. The severity of BSS of patients could be assessed by their grades. Although BSS was the major syndrome type of UA, UA also had other syndromes, such as phlegm, qi, or blood deficiency. This study just included UA patients who had only BSS in BSS group. The diagnosis about BSS of UA patients were made by 3 appointed TCM practitioners. Patients were included in the study only if the 3 practitioners reported consistent results. This ensured that all of the selected patients had typical manifestations of BSS.

Patients who had received thrombolytic therapy in the previous month were excluded from the study. Patients with stable angina, MI, heart failure, valvular heart disease, dilated cardiomyopathy, malignant tumor, advanced liver disease, renal failure, autoimmune diseases, and other inflammatory diseases and women who were pregnant and breast-feeding were excluded from the study. Control subjects (n = 20) were healthy volunteers, recruited from the same population and the same area of China as the patients’ group. Total RNAs isolated from 5 BSS of UA patients and 5 healthy volunteers were used for gene expression oligonucleotide microarray and microRNA microarray. The results obtained from bioinformatics analysis of microarray were then prospectively tested in a validation cohort of 30 BSS of UA patients,
Table 1: The grading system in quantifying blood stasis syndrome diagnosis standards.

| Signs and symptom                        | Point |
|------------------------------------------|-------|
| Purple tongue (less severe)              | 8     |
| Resistance to pressure in lower abdomen (less severe) | 8     |
| Choppy pulse                             | 10    |
| Dark stool (Melena)                      | 10    |
| Pathogenic nodules                       | 10    |
| Distended veins under tongue (less severe) | 8     |
| Irregular pulse                          | 8     |
| No pulse                                 | 10    |
| Distended veins in abdominal wall        | 10    |
| Hypodermal ecchymoses (less severe)      | 8     |
| Persistent angina pectoris               | 10    |
| General fixed pain                       | 8     |
| Dark red lips and gums                   | 6     |
| Small vessels                            | 5     |
| Numb extremities                         | 5     |
| Surgery history                          | 5     |
| Mucosal membrane of palate (+) (less severe) | 4     |
| Paralysis in extremities (less severe)   | 5     |
| Psychiatric abnormality (Irritability)   | 4     |
| Rough skin                               | 4     |
| Complete blood viscosity (+)             | 10    |
| Blood plasma viscosity (+)               | 5     |
| External clot net weight (+)             | 10    |
| External clot total weight (+)           | 8     |
| Increase in platelet aggregation (less severe) | 4     |
| Abnormality in blood clot elasticity     | 8     |
| Microcirculation obstruction             | 10    |
| Hemodynamics obstruction                 | 10    |
| Decrease in fiber dissolution activity   | 10    |
| Resistance in platelet release           | 10    |
| Pathogenic scan (+) for blood stasis     | 10    |
| Blood vessel obstruction by new technology analysis | 10    |

Grades <19 points are categorized as non-BSS. Grades 20–49 points are categorized as less severe BSS. Grades >50 points are categorized as more severe BSS [16, 22].

30 non-BSS of UA patients, and 15 healthy volunteers. The study complied with the Declaration of Helsinki and was approved by the local ethics committee. All individuals gave their written informed consent to participate in the study.

2.2. Plasma Collection and RNA Isolation. Whole blood samples (10 mL) were drawn from each of the 85 participants (35 UA patients with BSS, 30 non-BSS of UA patients and 20 healthy volunteers) with 19-gauge needle for clean venipuncture of an antecubital vein on the following morning after arrival. Timing of phlebotomy of UA patients compared with onset of chest pain was <24 h. Blood was drawn into EDTA-containing tubes and PBMCs were isolated by performing density gradient centrifugation with Ficoll (Invitrogen, Carlsbad, CA, USA). Total RNAs were extracted from PBMCs using Trizol reagent (Invitrogen) according to the manufacturer's instruction. RNA quantity and purity were assessed using NanoDrop ND-1000 (Thermo Scientific, Waltham, MA, USA). Pass criteria for absorbance ratios were established at A260/A280 ≥ 1.8 and A260/A230 ≥ 1.5 indicating acceptable RNA purity. RNA Integrity Number (RIN) values were ascertained using Agilent RNA 6000 Nano assay (Agilent Technologies, Santa Clara, CA, USA). Pass criteria for RIN value were established at ≥6 indicating acceptable RNA integrity. Genomic DNA contamination was evaluated by gel electrophoresis. The RNA samples were stored at −80°C until analysis.

2.3. mRNA Expression Profiling. Total RNAs of 10 participants (5 UA patients with BSS and 5 healthy volunteers) were used for mRNA expression profiling by the Human Whole Genome OneArray v5 (Phalanx Biotech Group, Hsinchu, Taiwan). It contained 30275 DNA oligonucleotide probes, and each probe was a 60-mer designed in the sense direction. Among the probes, 29187 probes corresponded to the annotated genes in RefSeq v38 and Ensembl v56 database. Besides, 1088 control probes were also included. Fluorescent aRNA targets were prepared from 1 or 2.5 μg total RNA samples using OneArray Amino Allyl aRNA Amplification Kit (Phalanx Biotech Group) and Cy5 dyes (Amersham Pharmacia, Piscataway, NJ, USA). Fluorescent targets were hybridized to the Human Whole Genome OneArray with Phalanx Hybridization buffer using Phalanx Hybridization System. After 16 hrs hybridization at 50°C, nonspecific binding targets were washed away by three different washing steps (Wash I 42°C 5 minutes; Wash II 42°C 5 minutes, 25°C 5 minutes; Wash III rinse 20 times), and the slides were dried by centrifugation and scanned by Axon 4000B scanner (Molecular Devices, Sunnyvale, CA, USA). The intensities of each probe were obtained by GenePix 4.1 software (Molecular Devices). The raw intensity of each spot was loaded into Rosetta Resolver System (Rosetta Biosoftware, Seattle, WA, USA) to process data analysis. The error model of Rosetta Resolver System could remove both systematic and random errors form the data. Those probes with background signals were filtered out. Probes that passed the criteria were normalized by 50% median scaling normalization method. Normalized spot intensities were transformed to mRNA expression log2 ratios between the UA patients with BSS and healthy controls.

2.4. MicroRNA Expression Profiling. We performed miRNA expression profiling in the same set of samples (5 UA patients with BSS and 5 healthy volunteers) that were used in
the analysis of mRNA microarray. MiRNA microarray analysis was performed by using the Human miRNA OneArray v4 (Phalanx Biotech Group). It contained triplicated 1884 unique miRNA probes from Human (miRNA microarray v18) and 144 experimental control probes. Small RNA was preenriched by Nanoseplook (Pall Corporation, Port Washington, NY, USA) from 2.5 μg total RNA samples and labeled with miRNA ULS Labeling Kit (Kreatech Diagnostics, Vierweg, Amsterdam, The Netherlands). Labeled miRNA targets were hybridized to the Human miRNA OneArray v4 with OneArray Hybridization System. After 16 hrs hybridization at 37°C, nonspecific binding targets were washed away by three different washing steps (Wash I 37°C 5 minutes; Wash II 37°C 5 minutes; Wash III rinse 20 times), and the slides were dried by centrifugation and scanned by an Axon 4000B scanner (Molecular Devices). The Cy5 fluorescent intensities of each probe were analyzed by GenePix 4.1 software (Molecular Devices). The raw intensity of each probe was processed by R program. Probes that passed the criteria were normalized by 75% median scaling normalization method. Normalized spot intensities were transformed to miRNA expression log ratios between the UA patients with BSS and healthy controls.

2.5. Integrated Bioinformatics Analysis of the mRNA and MiRNA Expression Profiles

2.5.1. Identification of Differentially Expressed mRNAs and miRNAs. The expressions of mRNAs with log2 ratio ≥ 1 or log2 ratio ≤ −1 and P value < 0.05 were defined as differential mRNAs. The expressions of miRNAs with log2 ratio ≥ 0.8 or log2 ratio ≤ −0.8 and P value < 0.05 were defined as differential miRNAs. Hierarchical clustering analysis combined with a heatmap was applied to evaluate the overall reproducibility and variation of 5 samples within each group and the differences between the 2 groups. An average linkage hierarchical clustering was performed with clustering software Cluster3.0 and Java TreeView-1.1.6r2 was applied to generate the heatmap [28, 29].

2.5.2. KEGG Pathway Analysis Using DAVID. There were thousands of deregulated genes; we cannot analyze the function of all these deregulated genes one by one, so we could only focus on the main functions of deregulated genes. We used DAVID Bioinformatics Resources 6.7 (the Database for Annotation, Visualization, and Integrated Discovery) [30], a comprehensive set of functional annotation tools for understanding the biological meaning behind large lists of genes, to identify enriched KEGG (Kyoto Encyclopedia of Genes and Genomes) pathways [31] information for differential mRNAs between UA patients with BSS and healthy controls. EASE Score, a modified Fisher Exact P Value, was used to measure the gene enrichment in annotation pathways and Benjamini-Hochberg False Discovery Rate was used as testing correction. The threshold of EASE Score was set 0.1. Because miRNAs were usually negatively correlated with target mRNAs and differentially expressed miRNAs were mainly upregulated, pathways enriched of downregulated mRNAs were chose for further analysis and downregulated mRNAs were marked in green on these pathways by Search & Color Pathway in KEGG [31]. MiRNAs which could regulate downregulated genes of these pathways were predicted by one of the 2 algorithms of DIANA-microT and Targetscan [32, 33]. If these predicted miRNAs were among the actually upregulated miRNAs, they were marked in red on these pathways.

2.5.3. Integrated miRNA/mRNA Network Analysis. MiRNAs were usually negatively correlated with target mRNAs and differentially expressed miRNAs in BBS with UA group were mainly upregulated, so upregulated miRNAs and downregulated mRNAs were uploaded into the miRTrail, a knowledge-based tool for integrative network analysis that allowed for studying the interactions between microRNAs and their target mRNAs [34]. For each upregulated miRNA, the target mRNAs were predicted by the respective web-resource microCosm and the prediction threshold was set at 0.01. The predicted target mRNAs were compared with the actually downregulated mRNAs in order to find the overlap between them. The miRNAs that could regulate these overlap mRNAs were ranked based on the number of deregulated target mRNAs and the top 5% were selected. The interactive network of selected miRNAs and actually deregulated target mRNAs was visualized by the network analyzers and viewers BiNA [35].

2.5.4. Protein-Protein Interactions Network Analysis. In the integrated miRNA/mRNA network, there were hundreds of upregulated mRNAs. To further understand the function of these miRNAs, we use a method of combing the protein-protein interactions (PPIs) network and hubs. Protein-Protein Interactions (PPIs) were commonly understood as physical contacts with molecular docking between proteins that occur in a cell or in a living organism in vivo [36]. Each of these interactions was specifically adapted to carry out certain biological functions. A PPIs network was represented as proteins as nodes and interactions between nodes are edges. To further understand the function of the upregulated miRNAs, a PPIs network for mRNAs in the miRNA/mRNA interactive network was built by Reactome FI, a Cytoscape plugin [37]. This plugin accessed the Reactome Functional Interaction (FI) network, a highly reliable, manually curated pathway-based protein functional interaction network covering close to 50% of human proteins, and allowed you to construct an FI subnetwork based on a set of genes by using linker genes. The PPIs network was visualized using the Cytoscape software [38].

Hubs were highly connected nodes in a network and vital for the proper function of a network [39]. CytoHubba, a Cytoscape plugin, was used to find the hubs of the PPIs network [40]. It evaluated node essentiality by topological characters. The degree of a node was the number of links incident to this node in a network and it was chose for topological analysis in the study. Top 10 essential nodes ranked by degree scores were selected as hubs from the network.
2.6. Reverse Transcription and qRT-PCR of miRNA and mRNA. Combining pathway analysis with network analysis, hsa-miR-146b-5p and has-miR-199a-5p seemed to be the most involved miRNAs in UA patients with BSS. Thus, to support the robustness of our analysis, differences in expression of the 2 miRNAs and 2 downregulated target mRNAs (CALR and TP53) were validated in an independent cohort of 30 UA patients with BSS, 30 non-BSS of UA patients, and 15 healthy controls by qRT-PCR. To assay for miRNAs, 1 μg of purified total RNA generated cDNA using the QuantiMir RT Kit, following the manufacturer’s instructions (System Biosciences, Mountain View, CA, USA). qRT-PCR was performed using 2X SYBR Green qPCR Mastermix (Roche Applied Science, Indianapolis, IN, USA) 7900HT Fast Real-Time PCR System (Applied Biosystems, Carlsbad, CA, USA). The mature sequences of hsa-miR-146b-5p and has-miR-199a-5p were used as the forward primers, and the 3′ universal reverse primer provided from the QuantiMir RT Kit (System Biosciences) was used as the reverse primer. The human U6 RNA was amplified in parallel as the internal control. All mRNA primer sequences were summarized in Table 4. 30 UA patients with BSS, 30 non-BSS of UA patients with non-BSS had angiographically documented CAD. 20 healthy volunteers were selected as the healthy controls. 5 UA patients with BSS and 5 healthy volunteers were used for miRNA and miRNA microarray analysis. The clinical characteristics of the 2 groups of microarray analysis were summarized in Table 4. 30 UA patients with BSS, 30 UA patients with non-BSS and 15 healthy volunteers were used for qRT-PCR. The clinical characteristics of the 3 groups of qRT-PCR were summarized in Table 5. There were no significant differences in age, percentage of males, BMI (body mass index), percentage of active smoker, history of type 2 diabetes mellitus, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, and calcium-channel blockers medication between UA patients with BSS and healthy control group in microarray analysis. There were significant differences in other clinical parameters between the two

### Table 2: The forward primers of miRNAs for amplification.

| Accession     | Name            | Sequence                  |
|---------------|-----------------|----------------------------|
| MIMAT0002809  | hsa-miR-146b-5p | Forward 5′-TGAGAACTGAATTCCATAGGCT-3′ |
| MIMAT000231   | hsa-miR-199a-5p | Forward 5′-CCCATGGTTCAGACTACCTGTTC-3′ |
| X07425.1      | Human U6 snRNA  | Forward 5′-CGCAAGGATGACACGCAAATTC-3′ |

### Table 3: The primers of mRNAs for amplification.

| Accession     | Name | Sequence |
|---------------|------|----------|
| NM_004343.3   | CALR | Forward 5′-GGCAATGAGGACTTTCTAAT-3′ |
|               |      | Reverse 5′-GGTCTTGCCCTTGATGGAAGAT-3′ |
| BC003596.1    | TP53 | Forward 5′-GGAGTTGGACATACCCAGTTAGTT-3′ |
|               |      | Reverse 5′-TGCTAGAATGGGCTGTATTGAAC-3′ |
| NG_007073.2   | GAPDH| Forward 5′-CAAGTGTCTGATGACGACC-3′ |
|               |      | Reverse 5′-CCATGGAAAGGCTGGG-3′ |

2.7. Statistics. All results for continuous variables were expressed as means ± SEM, if not stated otherwise. For group-wise comparisons, Man-Whitney test (2 groups), ANOVA, Kruskal-Wallis test (n groups), or Student’s t-test (2 groups) were used as appropriate. For categorical variables, the Chi-square test or Fischer’s exact test was used. All tests were performed 2-sided and a significance level of P < 0.05 was considered to indicate statistical significance. For all statistical analyses, the statistical software SPSS 16.0 (Statistical Package for the Social Sciences, Chicago, IL, USA) for Windows was used. GraphPad Prism 5 (GraphPad software, San Diego, CA, USA) was used to draw bar and box charts.

3. Results

3.1. Basic Clinical Characteristics of Subjects. A total of 85 subjects were studied. 35 UA patients with BSS and 30 UA patients with non-BSS had angiographically documented CAD. 20 healthy volunteers were selected as the healthy controls. 5 UA patients with BSS and 5 healthy volunteers were used for miRNA and miRNA microarray analysis. The clinical characteristics of the 2 groups of microarray analysis were summarized in Table 4. 30 UA patients with BSS, 30 UA patients with non-BSS and 15 healthy volunteers were used for qRT-PCR. The clinical characteristics of the 3 groups of qRT-PCR were summarized in Table 5. There were no significant differences in age, percentage of males, BMI (body mass index), percentage of active smoker, history of type 2 diabetes mellitus, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, and calcium-channel blockers medication between UA patients with BSS and healthy control group in microarray analysis. There were significant differences in other clinical parameters between the two
Table 4: Clinical characteristics of subjects of microarray analysis.

|                      | UA with BSS (n = 5) | Controls (n = 5) | P value |
|----------------------|---------------------|-----------------|---------|
| Male gender (n)      | 3 (60%)             | 3 (60%)         | 0.596   |
| Age (years)          | 61.60 ± 4.93        | 61.00 ± 4.36    | 0.975   |
| BMI (kg/m²)          | 23.18 ± 3.89        | 23.24 ± 1.62    |         |
| Active smoker (n)    | 1 (20%)             | 1 (20%)         |         |
| BSS grades           | 72.80 ± 10.47       | 0               |         |
| Number of vessels (n)| 3.40 ± 0.89         | 0               |         |
| Hypertension (n)     | 4 (80%)             | 0               | 0.048   |
| Type 2 diabetes mellitus (n) |          | 0               | 0.008   |
| Total cholesterol (mmol/L) | 3.96 ± 1.45      | 4.02 ± 0.79     | 0.347   |
| LDL cholesterol (mmol/L) | 2.33 ± 1.01        | 2.51 ± 0.60     | 0.743   |
| HDL cholesterol (mmol/L) | 1.33 ± 0.35        | 1.30 ± 0.30     | 0.874   |
| Triglycerides (mmol/L) | 1.15 ± 0.50        | 1.09 ± 0.34     | 0.815   |
| CRP (mg/L)           | 3.64 ± 3.25         | 0.94 ± 0.09     | 0.018   |

Data represents means ± SEM. Abbreviations: ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; BMI: body mass index; BSS: blood stasis syndrome; HDL: high-density protein; CRP: C-reactive protein; LDL: low-density protein.

Table 5: Clinical characteristics of subjects of qRT-PCR.

|                      | UA with BSS (n = 30) | UA with non-BSS (n = 30) | Controls (n = 15) | P value |
|----------------------|----------------------|--------------------------|-------------------|---------|
| Male gender (n)      | 15 (50%)             | 15 (50%)                 | 8 (53.3%)         | 0.974   |
| Age (years)          | 57.06 ± 5.62         | 57.67 ± 6.43             | 56.87 ± 6.70      | 0.896   |
| BMI (kg/m²)          | 24.58 ± 1.52         | 24.10 ± 2.13             | 23.63 ± 1.52      | 0.231   |
| Active smoker (n)    | 17 (56.7%)           | 18 (60%)                 | 6 (40%)           | 0.429   |
| BSS Grades           | 73.93 ± 2.91         | 14.03 ± 2.22             | 0                 |         |
| Number of vessels (n)| 1.53 ± 0.94          | 1.57 ± 0.95              | 0                 |         |
| Hypertension (n)     | 22 (73.3%)           | 23 (76.7%)               | 0                 | 0.000   |
| Type 2 diabetes mellitus (n) | 14 (46.7%)      | 15 (50%)                 | 0                 | 0.001   |
| Total cholesterol (mmol/L) | 4.19 ± 0.83        | 4.19 ± 0.95              | 3.71 ± 0.76       | 0.172   |
| LDL cholesterol (mmol/L) | 2.60 ± 0.59         | 2.55 ± 0.58              | 2.37 ± 0.54       | 0.436   |
| HDL cholesterol (mmol/L) | 1.13 ± 0.21         | 1.12 ± 0.21              | 1.31 ± 0.29       | 0.032   |
| Triglycerides (mmol/L) | 1.79 ± 0.89          | 1.89 ± 1.04              | 1.03 ± 0.27       | 0.001   |
| CRP (mg/L)           | 3.93 ± 2.21          | 3.98 ± 2.26              | 2.73 ± 2.05       | 0.122   |

Data represents means ± SEM. Abbreviations: ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; BMI: body mass index; BSS: blood stasis syndrome; HDL: high-density protein; CRP: C-reactive protein; LDL: low-density protein.
Figure 1: Continued.
groups in microarray analysis ($P < 0.05$). There were no significant differences in age, percentage of males, BMI (body mass index), percentage of active smoker, total cholesterol, LDL cholesterol and CRP among UA patients with BSS, 30 UA patients with non-BSS and healthy control group in qRT-PCR analysis. There were significant differences in other clinical parameters among the 3 groups in qRT-PCR analysis ($P < 0.05$). There were no significant differences in HDL cholesterol, triglycerides (TG), hypertension, concurrent medication, and number of vessels between UA patients with BSS and UA patients with non-BSS in qRT-PCR analysis. There was significant difference in BSS grades between UA patients with BSS and UA patients with non-BSS in qRT-PCR analysis ($P < 0.05$).

3.2. Identification of Differentially Expressed mRNAs and miRNAs. A list of 1081 mRNAs was identified as differentially expressed between UA patients with BSS and the healthy controls (Figure 1(a)): 673 (56%) overexpressed and 408 (44%) underexpressed. The 1081 mRNAs were corresponding to 1206 nonunique probes because multiple probes in the microarray platform could be representative of a single mRNA. A list of 25 miRNAs was identified as differentially expressed between UA patients with BSS and the healthy control (Figure 1(b), Table 6): 23 (92%) overexpressed and 2 (8%) underexpressed.

3.3. Pathway Analysis Using DAVID. The KEGG pathway analysis of upregulated and downregulated mRNAs between UA patients with BSS and the healthy controls using DAVID was shown in Tables 7 and 8. Upregulated genes were enriched in 7 pathways and downregulated genes were enriched in 6 pathways. Among 7 pathways enriched of upregulated genes, NOD-like receptor signaling pathway, apoptosis pathway, and cytokine-cytokine receptor interaction pathway were closely related with UA. In the NOD-like receptor signaling pathway, ERBB2IP, BIRC2, BIRC3, TNFAIP3, RIPK2, CASP8, TAB2, CXCL1 and IL1B were upregulated. (Figure 2) In the apoptosis pathway, IL1A, IL1B, IL1RAP, IRAK3, PRKAR2B, BIRC2, BIRC3, BCL2, and CASP8 were upregulated. (Figure 3) In the cytokine-cytokine receptor interaction pathway, IL1A, IL1B, IL1RAP, IL7R, IL21R, CCR1, CXCR4, CXCL1, CXCL3, CXCL5, PF4V1, CCL20, IFNG, IFNGR1, OSM and ACVR2A were upregulated. (Figure 4) Among 6 pathways enriched of downregulated genes, the antigen processing and presentation pathway and p53 signaling pathway were closely related with UA, so the 2 pathways were chosen for further analysis. Upregulated miRNAs which could regulate downregulated genes of the 2 pathways were analyzed by one of the 2 algorithms of DIANAmT and Targetscan and mapped on the 2 pathways. In the antigen processing and presentation pathway, CALR, HLA-DRB1, HLA-DRB5, KLRC1, KLRC3, KIR3DS1 and KIR2DS3 were downregulated. CALR could be the target gene of miR-146a-5p, miR-146b-5p, miR-326, miR-589 and miR-625. HLA-DRB1 and HLA-DRB5 could be the target gene of miR-129-3p. KLRC1, KLRC3, KIR3DS1 and KIR2DS3 could be the target gene of miR-223. (Figure 5(a)) In the p53 signaling pathway, TP53, CDK4, STEAP3, SHISA5 and SESN2 were downregulated. TP53 could be the target gene of
Table 6: Differentially expressed miRNAs in UA patients with BSS versus healthy controls.

| ID          | Name              | UA with BSS/control ratio | P value |
|-------------|-------------------|---------------------------|---------|
| PH_mr_0001929 | hsa-miR-221-3p   | 1.58                      | 0.0440  |
| PH_mr_0000996 | hsa-miR-130a-3p  | 1.55                      | 0.0091  |
| PH_mr_0001948 | hsa-miR-199a-5p  | 1.41                      | 0.0438  |
| PH_mr_0003258 | hsa-miR-223-3p   | 1.38                      | 0.0324  |
| PH_mr_0002734 | hsa-miR-199a-3p  | 1.36                      | 0.0171  |
| PH_mr_0000023 | hsa-miR-126-3p   | 1.27                      | 0.0443  |
| PH_mr_0004749 | hsa-miR-4485     | 1.24                      | 0.0443  |
| PH_mr_0000176 | hsa-miR-151a-5p  | 1.17                      | 0.0387  |
| PH_mr_0000751 | hsa-miR-146b-5p  | 1.15                      | 0.0227  |
| PH_mr_0004446 | hsa-miR-22-3p    | 1.15                      | 0.0421  |
| PH_mr_0001886 | hsa-miR-150-3p   | 0.95                      | 0.0165  |
| PH_mr_0008005 | hsa-miR-1307-5p  | 0.94                      | 0.0051  |
| PH_mr_0001511 | hsa-miR-151a-3p  | 0.94                      | 0.0147  |
| PH_mr_0000436 | hsa-miR-92a-3p   | 0.94                      | 0.0301  |
| PH_mr_0001750 | hsa-miR-589-5p   | 0.94                      | 0.0188  |
| PH_mr_0001629 | hsa-miR-484      | 0.88                      | 0.0406  |
| PH_mr_0001844 | hsa-miR-326      | 0.87                      | 0.0068  |
| PH_mr_0001893 | hsa-miR-30d-5p   | 0.86                      | 0.0228  |
| PH_mr_0000911 | hsa-miR-129-1-3p | 0.86                      | 0.0379  |
| PH_mr_0001753 | hsa-miR-196a-3p  | 0.85                      | 0.0159  |
| PH_mr_0003163 | hsa-miR-423-3p   | 0.83                      | 0.0203  |
| PH_mr_0002404 | hsa-miR-625-5p   | 0.80                      | 0.0360  |
| PH_mr_0004525 | hsa-miR-4459     | −0.88                     | 0.0225  |
| PH_mr_0004803 | hsa-miR-4667-5p  | −1.02                     | 0.0419  |

Table 7: The pathways related to the upregulated mRNAs between UA patients with BSS and healthy controls.

| KEGG pathway                     | Number of genes | P value |
|----------------------------------|-----------------|---------|
| hsa04621: NOD-like receptor signaling pathway | 9               | 0.0024  |
| hsa04210: apoptosis              | 9               | 0.0182  |
| hsa03040: spliceosome            | 11              | 0.0228  |
| hsa04640: hematopoietic cell lineage | 8               | 0.0469  |
| hsa05130: pathogenic Escherichia coli infection | 6               | 0.0672  |
| hsa03018: RNA degradation        | 6               | 0.0672  |
| hsa04060: cytokine-cytokine receptor interaction | 16              | 0.0790  |

Table 8: The pathways related to the downregulated mRNAs between UA patients with BSS and healthy controls.

| KEGG pathway                     | Number of genes | P value |
|----------------------------------|-----------------|---------|
| hsa05332: graft-versus-host disease | 5               | 0.0121  |
| hsa04612: antigen processing and presentation | 7               | 0.0121  |
| hsa04115: p53 signaling pathway | 5               | 0.0722  |
| hsa00280: valine, leucine, and isoleucine degradation | 4               | 0.0812  |
| hsa00510: N-Glycan biosynthesis | 4               | 0.0901  |
| hsa00532: chondroitin sulfate biosynthesis | 3               | 0.0913  |

3.4. Integrated miRNA/mRNA Network Analysis. 23 upregulated miRNAs and 408 downregulated mRNAs were uploaded into miRTrail. 4250 target mRNAs were predicted by microCosm. 115 mRNAs were found to be the overlap between the predicted target mRNAs and the actually downregulated mRNAs. 6 upregulated miRNAs were selected according to the top 5% of the rank based on the number of deregulated target mRNAs. The interactive network of 115 downregulated mRNAs and 6 upregulated miRNAs was
3.5. Protein-Protein Interactions Network Analysis. Based on the integrated miRNA/mRNA network analysis results, a PPIs network for 115 downregulated mRNAs was built by Reactome FI plugin (Figure 7). It included 124 nodes and 291 edges. Hubs of the PPIs network were found by CytoHubba. Hubs were MAPK14, AKT1, EP300, HDAC1, TP53, E2F1, SMAD3, GNB1, MYC, and SRC (Figure 8). The degrees of hubs were listed in Table 9.

3.6. qRT-PCR of miRNA and mRNA. Representative qRT-PCR results for hsa-miR-146b-5p, has-miR-199a-5p, CALR, and TP53 were reported in Figure 9. Hsa-miR-146b-5p and has-miR-199a-5p were upregulated, while CALR and TP53 were downregulated in UA patients with BSS compared to UA patients with non-BSS or the healthy control (P < 0.05). These results confirmed our bioinformatics analysis.

4. Discussion

In this study, using a systems biology approach we exploited critically deregulated miRNAs and mRNAs involved in pathogenesis of BSS of UA and potential biomarkers for BSS of UA. Our integration strategy started by extracting differentially expressed mRNAs and miRNAs between UA patients with BSS and the healthy control from the microarray analysis and then took them to integrative bioinformatics analysis. The robustness of our analysis was confirmed by qRT-PCR.

4.1. mRNA Expression Data. Regarding thousands of deregulated genes, we cannot analyze the function of all these deregulated genes one by one, so we only focused on the function of deregulated genes enriched in KEGG pathways. The function of deregulated genes in the pathways related with UA would be discussed in the following part to understand the biomedical mechanisms of BSS of UA.

Among upregulated genes of NOD-like receptor signaling pathway (Figure 2), RIPK2 was a key mediator of the activation of apoptosis pathway [42]. Apoptosis was known...
to occur in advanced plaques at higher levels, comparing both patients with stable angina and control subjects [43, 44]. The apoptosis of vascular smooth muscle cells (VSMCs) and macrophages altered plaque composition and made it prone to disruption and acute luminal thrombosis [45, 46]. CASP8, an important executor of apoptosis [47], was upregulated in NOD-like receptor signaling pathway. The upregulation of CASP8 indicated active apoptosis in BSS of UA. RIPK2 was critical for both the innate and adaptive immune pathways [48]. However, there were fewer studies about the role of RIPK2 in UA. Our study showed that RIPK2 may contribute to the apoptosis in BSS of UA by activating CASP8. This indicated the innate and adaptive immunity may regulate the apoptosis in BSS of UA. Except RIPK2, CXCL1, and IL1B were also key upregulated genes in the NOD-like receptor signaling pathway. Studies showed that CXCL1 could support arrest of human monocytic cell lines and primary monocytes under flow conditions and may play an important role in monocyte recruitment to atherosclerotic lesions [49]. IL-1β was a proinflammatory cytokine with pleiotropic effects implicated in the various stages of atherosclerosis [50, 51]. Studies showed that IL-1β was at higher levels in UA patients, comparing both stable angina ones and control subjects in peripheral blood [52, 53]. Both CXCL1 and IL1B were important proinflammatory mediators, and they promoted the inflammation. Inflammation can regulate the integrity of the interstitial collagen of the plaque’s fibrous cap and be responsible for plaque rupture and triggering UA [54]. The upregulation of CXCL1 and IL1B may promote inflammation in BSS of UA. In the apoptosis pathway, the effect of upregulation of IL1B and CASP8 was discussed. IL1A, IL1B, and IL1RAP all belonged to the IL-1 family. IL-1 was proinflammatory and destabilized the proteinaceous scaffold of the cap by inducing up-regulation of matrix metalloproteinases [55]. The upregulation of IL-1 and IL1RAP may promote the inflammation in BSS of UA. IRAK3 was a kinase-deficient member of the TLR/IRAK family that was an important negative regulator of TLR signaling and regulated innate immune homeostasis [56]. The latest research showed that IRAK3 was a key inhibitor of TLR2/NF-κB mediated chronic inflammation [57]. Although the role of IRAK3 in UA was not defined, our study showed that the upregulation of IL-1 may activate IRAK3 to regulate innate immunity and inhibit inflammation. PRKAR2B was one of the regulatory subunits bound to cAMP. The activation of cAMP/PKA pathway induced the phosphorylation and inactivation of BAD, a proapoptotic protein [58]. BIRC2 and BIRC3 were members of the inhibitor of apoptosis protein (IAP) family [59]. BCL2 was an antiapoptotic factor, and it inhibited the apoptosis of VSMCs and macrophages in advanced
IFNG was found to be highly produced by CD4+ T cells in PBMCs from UA patients, comparing both stable angina and STEMI cases [60, 61]. The upregulation of IFNG and its receptor (IFNGR1) may promote inflammation and stabilize the plaque in BSS of UA [62]. PRKAR2B was demonstrated to contribute to plaque destabilization by inducing vascularization of the lesion due to its angiogenic properties and involving in plaque thrombogenicity [71]. Taken together, the upregulation of these cytokines and their receptors may promote the inflammation and destabilize the plaque in BSS of UA.

In the antigen processing and presentation pathway, CALR (calreticulin) was an ER (endoplasmic reticulum) luminal Ca2+-buffering chaperone, and involved in regulation of intracellular Ca2+ homoeostasis and ER Ca2+ capacity [72]. Recent studies showed that enhanced CALR expression in mature cardiomyocytes disrupted intracellular calcium regulation, leading to calcium-dependent apoptosis [73]. It was reported that fibroblast growth factor 2 (FGF-2) induced angiogenesis after sustained ischemia with downregulation of CALR expression in myocardium and the CALR expression was negatively correlated to angiogenesis [74]. In addition, the binding of CALR to CD91 stimulated proinflammatory responses [75]. The downregulation of CALR may attenuate apoptosis and inflammation, and promote angiogenesis in BSS of UA. HLA-DRB1 and HLA-DRB5 belonged to the HLA class II molecule which played a central role in the immune response [76]. In the antigen processing and presentation pathway, HLA class II molecules were expressed on the surface of APCs and presented peptides derived from extracellular proteins to T cells [77]. The downregulation of HLA class II may inhibit the T-cell response in plaques of BSS of UA. KLRC1 and KLRC3 were members of the immunoglobulin superfamily and involved in the T-cell response against antigens in the unstable plaques.
were members of natural killer (NK) cell lectin-like receptors subfamily C. KIR3DS1 and KIR2DS3 were members of natural killer (NK) cell immunoglobulin-like receptors. These NK cell receptors played an important role in regulation of the immune response [78]. NK cells were identified in human and mouse atherosclerotic lesions and infiltrated the vessel wall and promoted atherosclerotic lesion development [79]. The downregulation of these NK cell receptors may indicate the suppression of immune response mediated by NK cells in BBS of UA. In the p53 signaling pathway, TP53 (p53) responded to diverse cellular stresses to regulate target genes that induced cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism [80]. The increased TP53 expression was related with the enlargement of necrotic cores, plaque rupture, and clinical manifestations of carotid plaques. Concomitant increases of TP53 level may lead to
the apoptosis and atheroma progression in patients with carotid atherosclerosis [81]. The downregulation of TP53 may inhibit the apoptosis in BSS of UA. CDK4 was a catalytic subunit of the cyclin-dependent kinase. In proliferating cells, the activation of CDK4 was necessary for cell cycle progression [82]. Proliferation of VSMCs and macrophages was observed in atherosclerotic plaques [83]. There was evidence that oxLDL-stimulated VSMC proliferation was associated with significant increases in the expression of CDK4 [84]. The downregulation of CDK4 may inhibit cell proliferation in BSS of UA. STEAP3 regulated apoptosis and the cell cycle [85]. SHISA5 encoded a protein named Scotin. Scotin induced apoptosis by causing cell cycle arrest [86]. SESN2 played a role in the regulation of cell growth and survival [87]. There was still lack of research about the function of STEAP3, SHISA5, and SESN2 in UA. Whether these genes involved in the regulation of apoptosis of BSS in UA was worth further exploring.
Figure 7: The PPIs network of downregulated mRNAs of the miRNA/mRNA interactive network. Rectangular represented downregulated mRNAs and round represented added interactive mRNAs. The interactions between two mRNAs extracted from pathways were shown as solid lines while those predicted interactions were shown as dashed lines. Extracted interactions involved in activation, expression regulation, or catalysis were shown with an arrowhead on the end of the line, while interactions involved in inhibition were shown with a "T" bar.

Figure 8: Hubs of the PPIs network.
Putting the functional analysis of pathways together, most of the upregulated genes in BSS of UA were implicated in inflammation, apoptosis, and innate and adaptive immunity, and most of the downregulated genes in BSS of UA were implicated in apoptosis, angiogenesis, inflammation, immune response, and cell cycle arrest. The inflammation and immune response in BSS of UA was in accordance with previous reports demonstrating inflammatory and immune related genes were related to BSS of CAD by microarray analysis [88]. In addition, the analysis showed that apoptosis was involved in BSS of UA and some genes related with the regulation of cell cycle may regulate apoptosis in BSS of UA. Apoptosis added a new layer for the complex pathophysiology of BSS of UA. Interestingly, we found that some genes of the active innate and adaptive immunity may regulate inflammation and apoptosis in BSS of UA, such as RIPK2 and IRAK3. The deregulation and imbalance of apoptosis, inflammation and immunity could be the key biomedical mechanisms in BSS of UA.

4.2 miRNA Expression Data. Compared with healthy controls, the miRNA expression of BSS of UA was mainly upregulated. Considering the negative regulation of miRNA on gene, it indicated that miRNAs may mainly play an inhibitory role in BSS of UA. Among the upregulated miRNAs, miR-126, miR-129, miR-146, miR-150, miR-151a-3p, miR-199a-5p, miR-221, miR-223, miR-30d, miR-326 and miR-92a were reported to be upregulated in PBMCs of CAD patients compared with healthy controls [89–91]. There were compelling evidences that some of these upregulated miRNAs played fundamental roles in the development and progression of UA. miR-126 was an endothelial cell-restricted microRNA and enhanced the proangiogenic action of VEGF and FGF and promoted blood vessel formation [92]. miR-130a downregulated the antiangiogenic homeobox proteins GAX and HoxA5 [93]. The proangiogenic properties of miR-126 and miR-130a suggested that their upregulation may enhance angiogenesis in BSS of UA. In human blood cells, miR-150 was selectively packaged into microvesicles (MVs) and actively secreted. Secreted monocytic miR-150 enhanced targeted endothelial cell migration. MVs isolated from the plasma of patients with atherosclerosis contained higher levels of miR-150, and they more effectively promoted endothelial cell migration than MVs from healthy donors [94]. The upregulation of miR-150 may promote the endothelial cell migration in BSS of UA. miR-221 was necessary for VSMC proliferation and vascular neointimal lesion formation [95]. The upregulation of miR-221
may promote VSMC proliferation in BSS of UA. miR-92a was highly expressed in endothelial cells and regulated angiogenic functions of endothelial cells. Forced overexpression of miR-92a in endothelial cells blocked angiogenesis in vitro and in vivo [96]. Upregulation of miR-92a may hinder angiogenesis in BSS of UA.

4.3. Integrated miRNA/mRNA Network Analysis. Among up-regulated miRNAs, miR-146b-5p, miR-199a-3p, miR-199a-5p, miR-326, miR-423-3p, and miR-484 were found to be key deregulated miRNAs in miRNA/mRNA network. MAPK14, AKT1, EP300, HDAC1, TP53, E2F1, SMAD3, GNB1, MYC, and SRC were found to be hubs of the PPI network of downregulated target genes of the 6 miRNAs. Among the hubs, EP300, HDAC1, TP53, E2F1, SMAD3, and MYC were involved in the regulation of cell cycle [80, 97–101]. AKT1 and TP53 were involved in the regulation of apoptosis [80, 102]. MAPK14, AKT1, and SRC were involved in the regulation of angiogenesis [103–105]. It indicated that downregulated target genes of the 6 miRNAs were mainlyfunctioned in the regulation of cell cycle, apoptosis, and angiogenesis. This result was partly consistent with the pathway analysis of downregulated genes. Interestingly, TP53 was confirmed by both pathway and network analysis to be the key downregulated target genes.

Compares the network analysis with pathway analysis, we chose miR-146b-5p and miR-199a-5p and their target genes for further analysis for 2 reasons. First, miR-146b-5p and miR-199a-5p were proved to be key upregulated miRNAs in both pathway and network analysis. Second, CALR and TP53 were the key downregulated genes in BSS of UA, while CALR was the target gene of miR-146a-5p and TP53 was the target gene of miR-199a-5p. Although there was lack of research about the role of miR-146b-5p in UA, miR-146b was demonstrated to be rapidly induced in human monocytes in response to a variety of microbial components and pro-inflammatory cytokines [106]. It was reported that miR-146b decreased the expression of TNFα, IL-1B, and IL-6 in THP-1 monocytes [106, 107]. Other studies showed that IL-1 receptor signaling initiated both miR-146b upregulation and cytokine secretion, and that miR-146b was expressed in response to rising inflammatory cytokine levels and suppressed IL-6 and IL-8 secretion in primary human fibroblasts [108]. Moreover, miR-146b was induced by the potent proresolving mediator RvD1 in human macrophages in the resolution of inflammation and decreased protein levels of proinflammatory IL-8 and RANTES [109]. Furthermore, a recent study showed that miR-146b-5p, decreased in monocytes during obesity, was a major mediator of the anti-inflammatory action of globular adiponectin [110]. Collectively, all these studies implied that miR-146b-5p was induced in the inflammation and played an anti-inflammatory role in innate immunity. According to the pathway analysis, CALR could be the target gene of miR-146b-5p and upregulation of miR-146b-5p may induce the downregulation of CALR. According to functional analysis, both upregulation of miR-146b-5p and downregulation of CALR could attenuate the inflammation, and it implied that miR-146b-5p may attenuate inflammation by targeted repression of CALR in BSS of UA. Moreover, if CALR was confirmed to be the target gene of miR-146b-5p, miR-146b-5p may also function to inhibit apoptosis and promote angiogenesis by suppressing CALR in BSS of UA. miR-199a was reported to be acutely downregulated in cardiomyocytes in hypoxia and replenishing miR-199a during hypoxia reduced apoptosis [111]. According to the pathway analysis, TP53 could be the target gene of miR-199a-5p and upregulation of miR-199a-5p may induce the downregulation of TP53. According to functional analysis, both upregulation of miR-199a-5p and downregulation of TP53 could inhibit apoptosis, and it implied that miR-199a-5p may inhibit apoptosis by targeted repression of TP53 in BSS of UA.

Based on functional enrichment analysis of upregulated genes, there was active inflammation, apoptosis, and immune response in BSS of UA. Intriguingly, upregulation of miR-146b-5p and miR-199a-5p may extenuate inflammation and apoptosis in BSS of UA. Analysis of miR-146b-5p and miR-199a-5p expression unveiled a pattern of induction in response to inflammation and apoptosis in BSS of UA. The expression pattern of miR-146b-5p and miR-199a-5p in BSS of UA compared with healthy control were more like consequences than causes. Such a pattern was partly supported by the studies about the role of miR-146b in inflammation. There were evidences that pro-inflammatory cytokines could induce the upregulation of miR-146b which in return extenuate inflammation as part of a negative feedback regulation loop [106]. In addition, the miR-146b regulatory circuit just fine-tuned inflammation related signaling, rather than totally abrogating the signal [106]. Whether apoptosis induced the upregulation of miR-199a-5p and miR-199a-5p functioned as a negative feedback regulation loop to inhibit apoptosis was worth further exploring.

The present study revealed that microRNAs and mRNAs of PBMCs might be used as biomarkers for BSS of UA patients. Compared with healthy controls, levels of miR-146b-5p and miR-199a-5p were significantly higher, while levels of CALR and TP53 were significantly lower in BSS of UA patients. These miRNAs and mRNAs were closely related with BSS of UA patients. They might serve as biomarkers for distinguishing BSS of UA patients from healthy controls.

To confirm this result, miR-146b-5p and miR-199a-5p and their downregulated target genes (CALR and TP53) were selected to validate the expression level in an independent cohort of 30 BSS of UA patients, 30 non-BSS of UA patients and 15 healthy controls by qRT-PCR. Compared with healthy controls and non-BSS of UA patients, significant upregulation of miR-146b-5p and miR-199a-5p and downregulation of CALR and TP53 were proven. It confirmed the robustness of the expression pattern of miR-146b-5p, miR-199a-5p, CALR and TP53 in BSS of UA patients.

However, research limitations existed in our study. First, the sample size was small, and clinical studies with larger cohorts of BSS of UA patients and healthy controls were definitely required to extensively evaluate the miRNAs and mRNAs as practical biomarkers in comparison with the diagnostic criteria and scale of BSS, as well as the false-positive rate. Second, there was lack of validation by Western blot. Because TCM syndrome differentiation was based on
a collection of multiple symptoms and signs, the related biomedical mechanisms were likely quite complex. Thus, various miRNAs, genes, and intricate interactions were contained in the results, which made short time validation of results difficult. Nonetheless, the present study laid the groundwork for future efforts to identify and develop miR-146b-5p, miR-199a-5p, CALR and TP53 as a novel class of blood-based biomarkers for BSS of UA patients. According to these results, larger cohort investigations were designed to validate the diagnostic sensitivity and specificity of miR-146b-5p and miR-199a-5p as biomarkers. In addition, future studies will be performed to clarify the pathophysiological role of circulating miRNAs during pathogenesis of BSS of UA patients.

5. Conclusions

In general, the present study revealed that miR-146b-5p, miR-199a-5p, CALR, and TP53, which were related to the negative feedback regulation loop to attenuate inflammation and apoptosis, were significant biomarkers of BSS of UA patients. The systems biology-based miRNA and mRNA expression biomarkers for BSS of UA may be useful for further stratification of UA patients when making decisions on treatments.

Authors’ Contribution

Jie Wang and Gui Yu contributed equally to this paper.

Conflict of Interests

All authors declare that they have no conflict of interests.

Acknowledgments

The current work was supported by the National Natural Science Foundation Project of China (no. 81173116). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the paper.

References

[1] R. S. Wright, J. L. Anderson, C. D. Adams et al., “2011 ACCF/AHA focused update of the guidelines for the management of patients with unstable angina/ Non-ST-elevation myocardial infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,” Circulation, vol. 123, no. 18, pp. 2022–2060, 2011.
[2] E. Braunwald, “Unstable angina and non-ST elevation myocardial infarction,” American Journal of Respiratory and Critical Care Medicine, vol. 185, no. 9, pp. 924–932, 2012.
[3] N. Kuzniatsova, E. Shantsila, A. Blann, and G. Y. H. Lip, “A contemporary viewpoint on aspirin resistance,” Annals of Medicine, vol. 44, no. 8, pp. 773–783, 2012.
[4] B. A. Golomb, M. A. Evans, J. E. Dimsdale, and H. L. White, “Effects of statins on energy and fatigue with exertion: results from a randomized controlled trial,” Archives of Internal Medicine, vol. 172, no. 15, pp. 1180–1182, 2012.
[5] Y. C. Zhang, B. J. Lu, M. H. Zhao, Y. Z. Rong, and R. M. Chen, “Effect of Shengmai injection on vascular endothelial and heart functions in patients with coronary heart disease complicated with diabetes mellitus,” Chinese Journal of Integrative Medicine, vol. 14, no. 4, pp. 281–285, 2008.
[6] F. Qin and X. Huang, “Guanxin II for the management of coronary heart disease,” Chinese Journal of Integrative Medicine, vol. 15, no. 6, pp. 472–476, 2009.
[7] Y. R. Jiang, Y. Miao, L. Yang et al., “Effect of Chinese herbal drug-containing serum for activating-blood and dispelling-toxin on ox-LDL-induced inflammatory factors’ expression in endothelial cells,” Chinese Journal of Integrative Medicine, vol. 18, no. 1, pp. 30–33, 2012.
[8] H. Y. Liu, W. Wang, D. Z. Shi et al., “Protective effect of Chinese herbs for supplementing qi, nourishing yin and activating blood circulation on heart function of patients with acute coronary syndrome after percutaneous coronary intervention,” Chinese Journal of Integrative Medicine, vol. 18, no. 6, pp. 423–430, 2012.
[9] M. Xue, H. J. Yin, C. F. Wu et al., “Effect of Chinese drugs for activating blood circulation and detoxifying on indices of thrombosis, inflammatory reaction, and tissue damage in a rabbit model of toxin-heat and blood stasis syndrome,” Chinese Journal of Integrative Medicine, vol. 19, no. 1, pp. 42–47, 2013.
[10] J. H. Zhang, H. C. Shang, X. M. Gao et al., “Compound salvia droplet pill, a traditional Chinese medicine, for the treatment of unstable angina pectoris: a systematic review,” Medical Science Monitor, vol. 14, no. 1, pp. RAI–RA7, 2008.
[11] X. Qiu, A. Miles, X. Jiang, X. Sun, and N. Yang, “Sulfotanshinone sodium injection for unstable angina pectoris: a systematic review of randomized controlled trials,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 203043, 17 pages, 2012.
[12] A. S. Ferreira and A. J. Lopes, “Chinese medicine pattern differentiation and its implications for clinical practice,” Chinese Journal of Integrative Medicine, vol. 17, no. 11, pp. 818–823, 2011.
[13] A. P. Lu, Z. X. Bian, and K. J. Chen, “Bridging the traditional Chinese medicine pattern classification and biomedical disease diagnosis with systems biology,” Chinese Journal of Integrative Medicine, vol. 18, no. 12, pp. 883–890, 2012.
[14] A. P. Lu and K. J. Chen, “Chinese medicine pattern diagnosis could lead to innovation in medical sciences,” Chinese Journal of Integrative Medicine, vol. 17, no. 11, pp. 811–817, 2011.
[15] K. W. Yao, Q. Y. He, F. Teng et al., “Logistic regression analysis of syndrome essential factors in patients with unstable angina pectoris,” Journal of Traditional Chinese Medicine, vol. 31, no. 4, pp. 273–276, 2011.
[16] K. J. Chen, “Blood stasis syndrome and its treatment with activating blood circulation to remove blood stasis therapy,” Chinese Journal of Integrative Medicine, vol. 18, no. 12, pp. 891–896, 2012.
[17] Y. Liu, H. J. Yin, D. Shi et al., “Chinese herb and formulas for promoting blood circulation and removing blood stasis and antiplatelet therapies,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 184503, 8 pages, 2012.
[18] M. Xue, K. J. Chen, and H. J. Yin, “Relationship between platelet activation related factors and polymorphism of related genes in patients with coronary heart disease of blood-stasis syndrome,” Chinese Journal of Integrative Medicine, vol. 14, no. 4, pp. 267–273, 2008.
Y. Liu, H. J. Yin, and K. J. Chen, “Research on the correlation between platelet gelosin and blood-stasis syndrome of coronary heart disease,” Chinese Journal of Integrative Medicine, vol. 17, no. 5, pp. 333–338, 2011.

Y. Liu, H. J. Yin, and K. J. Chen, “Research on the correlation between platelet gelosin and blood-stasis syndrome of coronary heart disease,” Chinese Journal of Integrative Medicine, vol. 17, no. 8, pp. 587–592, 2011.

K. W. Yao, F. Y. Chu, and J. Wang, “A clinical epidemiological study of the quantitative diagnosis scale of blood stasis syndrome,” Chinese Journal of Integrative Medicine, vol. 17, no. 3, pp. 200–204, 2011.

J. Wang, K. J. Chen, W. L. Weng et al., “Study on the diagnostic criteria of blood stasis syndrome,” Zhongguo Zhong Xi Yi Jie He Za Zhi, vol. 8, no. 10, pp. 585–589, 1988.

F. Y. Chu, J. Wang, K. W. Yao, and Z. Z. Li, “Effect of Xuefu Zhuyu Capsule on the symptoms and signs and health-related quality of life in the unstable angina patients with blood-stasis syndrome after percutaneous coronary intervention: a randomized controlled trial,” Chinese Journal of Integrative Medicine, vol. 16, no. 5, pp. 399–405, 2010.

Y. F. Liu, H. M. Yu, C. Zhang et al., “Effects of Quyu xiaoban capsules on clinical outcomes and platelet activation and aggregation in patients with unstable angina pectoris,” Journal of Alternative and Complementary Medicine, vol. 13, no. 5, pp. 571–576, 2007.

D. P. Bartel, “MicroRNAs: genomics, biogenesis, mechanism, and function,” Cell, vol. 116, no. 2, pp. 281–297, 2004.

E. van Rooij and E. N. Olson, “MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles,” Nature Reviews Drug Discovery, vol. 11, no. 11, pp. 860–872, 2012.

E. E. Creemers, A. J. Tijsen, and Y. M. Pinto, “Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease?” Circulation Research, vol. 110, no. 3, pp. 483–495, 2012.

M. J. L. de Hoon, S. Imoto, J. Nolan, and S. Miyano, “Open source clustering software,” Bioinformatics, vol. 20, no. 9, pp. 1453–1454, 2004.

A. J. Saldanha, “Java treeview—extensible visualization of microarray data,” Bioinformatics, vol. 20, no. 17, pp. 3246–3248, 2004.

D. W. Huang, B. T. Sherman, and R. A. Lempicki, “Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources,” Nature Protocols, vol. 4, no. 1, pp. 44–57, 2009.

M. Kanehisa, S. Goto, Y. Sato, M. Furumichi, and M. Tanabe, “KEGG for integration and interpretation of large-scale molecular data sets,” Nucleic Acids Research, vol. 40, no. 1, pp. D109–D114, 2012.

M. Maragkakis, M. Reczko, V. A. Simossis et al., “DIANA-microT web server: elucidating microRNA functions through target prediction,” Nucleic Acids Research, vol. 37, no. 2, pp. W273–W276, 2009.

B. P. Lewis, C. B. Burge, and D. P. Bartel, “Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets,” Cell, vol. 120, no. 1, pp. 15–20, 2005.

C. Laczny, P. Leidinger, J. Haas et al., “miRTrail—a comprehensive webserver for analyzing gene and miRNA patterns to enhance the understanding of regulatory mechanisms in diseases,” BMC Bioinformatics, vol. 12, no. 1, p. 36, 2012.

Y. Feng, H. Xu, D. Qu, F. Zheng, D. Z. Shi, and K. J. Chen, “Study on the tongue manifestations for the blood-stasis and toxin syndrome in the stable patients of coronary heart disease,” Chinese Journal of Integrative Medicine, vol. 17, no. 5, pp. 333–338, 2011.

D. P. Bartel, “MicroRNAs: genomics, biogenesis, mechanism, and function,” Cell, vol. 116, no. 2, pp. 281–297, 2004.

E. van Rooij and E. N. Olson, “MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles,” Nature Reviews Drug Discovery, vol. 11, no. 11, pp. 860–872, 2012.

E. E. Creemers, A. J. Tijsen, and Y. M. Pinto, “Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease?” Circulation Research, vol. 110, no. 3, pp. 483–495, 2012.

M. J. L. de Hoon, S. Imoto, J. Nolan, and S. Miyano, “Open source clustering software,” Bioinformatics, vol. 20, no. 9, pp. 1453–1454, 2004.

A. J. Saldanha, “Java treeview—extensible visualization of microarray data,” Bioinformatics, vol. 20, no. 17, pp. 3246–3248, 2004.

D. W. Huang, B. T. Sherman, and R. A. Lempicki, “Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources,” Nature Protocols, vol. 4, no. 1, pp. 44–57, 2009.

M. Kanehisa, S. Goto, Y. Sato, M. Furumichi, and M. Tanabe, “KEGG for integration and interpretation of large-scale molecular data sets,” Nucleic Acids Research, vol. 40, no. 1, pp. D109–D114, 2012.

M. Maragkakis, M. Reczko, V. A. Simossis et al., “DIANA-microT web server: elucidating microRNA functions through target prediction,” Nucleic Acids Research, vol. 37, no. 2, pp. W273–W276, 2009.
[52] A. Ozeren, M. Aydin, M. Tokac et al., “Levels of serum IL-1β, IL-2, IL-8 and tumor necrosis factor-α in patients with unstable angina pectoris,” Mediators of Inflammation, vol. 12, no. 6, pp. 361–365, 2003.

[53] A. D. Simon, S. Yazdani, W. Wang, A. Schwartz, and L. E. Rabbani, “Circulating levels of IL-1β, a prothrombotic cytokine, are elevated in unstable angina versus stable angina,” Journal of Thrombosis and Thrombolysis, vol. 9, no. 3, pp. 217–222, 2000.

[54] P. Libby, “What have we learned about the biology of atherosclerosis? The role of inflammation,” American Journal of Cardiology, vol. 88, no. 7, pp. 31–61, 2001.

[55] M. R. Alexander, C. W. Moehle, J. L. Johnson et al., “Genetic inactivation of IL-1 signaling enhances atherosclerotic plaque instability and reduces outward vessel remodeling in advanced atherosclerosis in mice,” The Journal of Clinical Investigation, vol. 122, no. 1, pp. 70–79, 2012.

[56] S. Janssens and R. Beyaert, “Functional diversity and regulation of different interleukin-1 receptor-associated kinase (IRAK) family members,” Molecular Cell, vol. 11, no. 2, pp. 293–302, 2003.

[57] M. Hulsmans, B. Geeraert, D. de Keyzer et al., “Interleukin-1 receptor-associated kinase-3 is a key inhibitor of inflammation in obesity and metabolic syndrome,” PLoS One, vol. 7, no. 1, Article ID e30414, 2012.

[58] B. S. Skalhegg and K. Tasken, “Specificity in the cAMP/PKA signaling pathway. Differential expression, regulation, and subcellular localization of subunits of PKA,” Frontiers in Bioscience, vol. 5, pp. D678–D693, 2000.

[59] Q. L. Deveraux and J. C. Reed, “IAP family proteins—suppressors of apoptosis,” Genes and Development, vol. 13, no. 3, pp. 239–252, 1999.

[60] O. Kutuk and H. Basaga, “Bcl-2 protein family: implications in vascular apoptosis and atherosclerosis,” Apoptosis, vol. 11, no. 10, pp. 1661–1675, 2006.

[61] T. Korn, E. Bettelli, W. Gao et al., “IL-21 initiates an alternative pathway to induce proinflammatory TH17 cells,” Nature, vol. 448, no. 7152, pp. 484–487, 2007.

[62] A. Zlotnik and O. Yoshie, “Chemokines: a new classification system and their role in immunity,” Immunity, vol. 12, no. 2, pp. 121–127, 2000.

[63] J. Hessongesser, H. P. Ng, M. Liang et al., “Identification and characterization of small molecule functional antagonists of the CCRI chemokine receptor,” Journal of Biological Chemistry, vol. 273, no. 25, pp. 15687–15692, 1998.

[64] A. Valenzuela-Fernández, T. Planchenault, F. Baleux et al., “Leukocyte elastase negatively regulates stromal cell-derived factor-1 (SDF-1)/CXCR4 binding and functions by aminoterminal processing of SDF-1 and CXCR4,” Journal of Biological Chemistry, vol. 277, no. 18, pp. 15677–15689, 2002.

[65] J. K. Damás, T. Waehre, A. Yndestad et al., “Stromal cell-derived factor-1/alpha in unstable angina: potential antiinflammatory and matrix-stabilizing effects,” Circulation, vol. 106, no. 1, pp. 36–42, 2002.

[66] D. F. Smith, E. Galkina, K. Ley, and Y. Huo, “GRO family chemokines are specialized for monocyte arrest from flow,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 289, no. 5, pp. H1976–H1984, 2005.

[67] C. A. Power, R. B. Furness, C. Brawand, and T. N. C. Wells, “Cloning of a full-length cDNA encoding the neutrophil-activating peptide ENA-78 from human platelets,” Gene, vol. 151, no. 1-2, pp. 333–334, 1994.
[83] D. Gordon, M. A. Reidy, E. P. Benditt, and S. M. Schwartz, “Cell proliferation in human coronary arteries,” Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 12, pp. 4600–4604, 1990.

[84] M. E. Zettler, M. A. Prociuk, J. A. Austria, H. Massaeli, G. Zhong, and G. N. Pierce, “OxLDL stimulates cell proliferation through a general induction of cell cycle proteins,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 284, no. 2, pp. H644–H653, 2003.

[85] B. J. Passer, V. Nancy-Portebois, N. Amzallag et al., “The p53-inducible TSAP6 gene product regulates apoptosis and the cell cycle and interacts with Nix and the Myt1 kinase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 5, pp. 2284–2289, 2003.

[86] R. K. Gupta, R. Tripathi, B. J. Naidu, U. K. Srivivas, and L. S. Shashidhara, “Cell cycle regulation by the pro-apoptotic gene scotin,” Cell Cycle, vol. 7, no. 15, pp. 2401–2408, 2008.

[87] M. C. Mairui, S. A. Malik, E. Morselli et al., “Stimulation of autophagy by the p53 target gene Sestrin2,” Cell Cycle, vol. 8, no. 10, pp. 1571–1576, 2009.

[88] X. J. Ma, H. J. Yin, and K. J. Chen, “Differential gene expression profiles in coronary heart disease patients of blood stasis syndrome in traditional Chinese medicine and clinical role of target gene,” Chinese Journal of Integrative Medicine, vol. 15, no. 2, pp. 101–106, 2009.

[89] S. Fichtlscherer, S. de Rosa, H. Fox et al., “Circulating microRNAs in patients with coronary artery disease,” Circulation Research, vol. 107, no. 5, pp. 677–684, 2010.

[90] C. Taurino, W. H. Miller, M. W. McBride et al., “Gene expression profiling in whole blood of patients with coronary artery disease,” Clinical Science, vol. 119, part 8, pp. 333–343, 2010.

[91] M. Hoekstra, C. A. C. van der Lans, B. Halvorsen et al., “The peripheral blood mononuclear cell microRNA signature of coronary artery disease,” Biochemical and Biophysical Research Communications, vol. 394, no. 3, pp. 792–797, 2010.

[92] S. Wang, A. B. Aurora, B. A. Johnson et al., “The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis,” Developmental Cell, vol. 15, no. 2, pp. 261–271, 2008.

[93] Y. Chen and D. H. Gorski, “Regulation of angiogenesis through a microRNA (miR-130a) that down-regulates antiangiogenic homeobox genes GAX and HOXAS,” Blood, vol. 111, no. 3, pp. 1217–1226, 2008.

[94] Y. Zhang, D. Liu, X. Chen et al., “Secreted monocytic miR-150 enhances targeted endothelial cell migration,” Molecular Cell, vol. 39, no. 1, pp. 133–144, 2010.

[95] X. Liu, Y. Cheng, S. Zhang, Y. Lin, J. Yang, and C. Zhang, “A necessary role of miR-221 and miR-222 in vascular smooth muscle cell proliferation and neointimal hyperplasia,” Circulation Research, vol. 104, no. 4, pp. 476–486, 2009.

[96] A. Bonauer, G. Carmona, M. Iwasaki et al., “MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice,” Science, vol. 324, no. 5935, pp. 1710–1713, 2009.

[97] A. W. Snowden, L. A. Anderson, G. A. Webster, and N. D. Perkins, “A novel transcriptional repression domain mediates p21WAF1/CIP1 induction of p300 transactivation,” Molecular and Cellular Biology, vol. 20, no. 8, pp. 2676–2686, 2000.

[98] H. S. Zhang, M. Gavin, A. Dahiya et al., “Exit from G1 and S phase of the cell cycle is regulated by repressor complexes containing HDAC-Rb-hSWI/SNF and RB-hSWI/SNF,” Cell, vol. 101, no. 1, pp. 79–89, 2000.

[99] B. Ren, H. Cam, Y. Takahashi et al., “E2F integrates cell cycle progression with DNA repair, replication, and G2/M checkpoints,” Genes and Development, vol. 16, no. 2, pp. 245–256, 2002.

[100] L. Li, Y. Iwamoto, A. Berezovskaya, and V. A. Boussiotis, “A pathway regulated by cell cycle inhibitor p27Kip1 and checkpoint inhibitor Smad3 is involved in the induction of T cell tolerance,” Nature Immunology, vol. 7, no. 11, pp. 1157–1165, 2006.

[101] B. Amati, T. D. Littlewood, G. I. Evan, and H. Land, “The c-Myc protein induces cell cycle progression and apoptosis through dimerization with Max,” The EMBO Journal, vol. 12, no. 13, pp. 5083–5087, 1993.

[102] A. H. Kim, G. Khursigara, X. Sun, T. F. Franke, and M. V. Chao, “Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1,” Molecular and Cellular Biology, vol. 21, no. 3, pp. 893–901, 2001.

[103] K. Issbrucker, H. H. Marti, S. Hippenstiel et al., “p38 MAP kinase—a molecular switch between VEGF-induced angiogenesis and vascular hyperpermeability,” The FASEB Journal, vol. 17, no. 2, pp. 262–264, 2003.

[104] E. Ackah, J. Yu, S. Zoellner et al., “Akt1/protein kinase Bα is critical for ischemic and VEGF-mediated angiogenesis,” Journal of Clinical Investigation, vol. 115, no. 8, pp. 2119–2127, 2005.

[105] B. P. Eliceiri, R. Paul, P. L. Schwartzberg, J. D. Hood, J. Leng, and D. A. Cheresh, “Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability,” Molecular Cell, vol. 4, no. 6, pp. 915–924, 1999.

[106] K. D. Taganova, M. P. Boldin, K. J. Chang, and D. Baltimore, “NF-kB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 35, pp. 12481–12486, 2006.

[107] L. A. O'Neill, F. J. Sheedy, and C. E. McCoy, “MicroRNAs: the fine-tuners of Toll-like receptor signalling,” Nature Reviews Immunology, vol. 11, no. 3, pp. 163–175, 2011.

[108] D. Bhaumik, G. K. Scott, S. Schokrpur et al., “MicroRNAs miR-146a/b negatively modulate the senescence-associated inflammatory mediators IL-6 and IL-8,” Aging, vol. 1, no. 4, pp. 402–411, 2009.

[109] A. Recchiuti, S. Krishnamoorthy, G. Fredman, N. Chiang, and C. N. Serhan, “MicroRNAs in resolution of acute inflammation: identification of novel resolvins D1-miRNA circuits,” The FASEB Journal, vol. 25, no. 2, pp. 544–560, 2011.

[110] M. Hulsmans, E. van Dooren, C. Mathieu, and P. Holvoet, “Decrease of miR-146b-5p in monocytes during obesity is associated with loss of the anti-inflammatory but not insulin signaling action of adiponectin,” PloS One, vol. 7, no. 2, Article ID e32794, 2012.

[111] S. Rane, M. He, D. Sayed et al., “Downregulation of miR-199a derepresses hypoxia-inducible factor-1α and sirtuin 1 and recapitulates hypoxia preconditioning in cardiac myocytes,” Circulation Research, vol. 104, no. 7, pp. 879–886, 2009.